PHAXIAM THERAPEUTICS S.A. PHAXIAM Therapeutics S.A. Stock Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.915 EUR | -1.19% |
|
0.00% | -36.63% |
| Sales 2023 | - | Sales 2024 * | 1.05M 1.12M | Capitalization | 17.92M 19.08M |
|---|---|---|---|---|---|
| Net income 2023 | -23M -24.48M | Net income 2024 * | - 0 | EV / Sales 2023 | - |
| Net Debt 2023 * | 3.3M 3.51M | Net Debt 2024 * | 1.7M 1.81M | EV / Sales 2024 * | 18.7 x |
| P/E ratio 2023 * |
-0.69
x | P/E ratio 2024 * |
-2.09
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 92.14% |
More Fundamentals
* Assessed data
More news
Latest transcript on PHAXIAM Therapeutics S.A.
More press releases
More news
| 1 week | -0.17% | ||
| Current month | -2.18% | ||
| 1 month | +0.69% | ||
| 3 months | -30.68% | ||
| 6 months | -34.49% | ||
| Current year | -36.63% |
1 week
2.87
2.95
1 month
2.833.00
3 years
2.6075.80
5 years
2.60114.60
10 years
2.60402.00
| Managers | Title | Age | Since |
|---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23-06-22 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23-06-22 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 23-06-22 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23-06-22 |
Gil Beyen
BRD | Director/Board Member | 62 | 23-06-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 2.915 | -1.19% | 1 337 |
| 24-04-17 | 2.95 | +0.34% | 2,729 |
| 24-04-16 | 2.94 | +0.17% | 3,723 |
| 24-04-15 | 2.935 | +0.17% | 3,460 |
| 24-04-12 | 2.93 | +0.34% | 9,489 |
Real-time Euronext Paris, April 18, 2024 at 11:35 am EDT
More quotes
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.95
EUR
Average target price
6.85
EUR
Spread / Average Target
+132.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.77% | 102B | |
| +2.15% | 96.84B | |
| -0.44% | 21.48B | |
| -18.54% | 20.82B | |
| -7.45% | 18.6B | |
| -40.31% | 16.81B | |
| -26.42% | 13.78B | |
| +0.47% | 13.4B | |
| +20.94% | 11.06B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock
